. home.aspx



Emgality maker Lilly courts payers with new migraine ER data

July 12, 2019 / Kyle Blankenship

Sales of Eli Lilly’s migraine and cluster headache med Emgality have lagged behind competitors from Amgen and Novartis and Teva Pharmaceutical. And in its push to bring payers on board, Lilly is deploying a full-court press with some new patient data. Just 5% of frequent migraine sufferers who seek emergency care for their symptoms are treated with a migraine prevention medication like Emgality, according to data from Lilly’s observational study of 20,000 trial patients, dubbed Overcome. Lilly said about 15% of the patient pool pursued emergency care within the last 12 months, presenting a clear gap in patients who are eligible for a preventive treatment but aren’t being prescribed one as well as a need for personalized care outside of the emergency room. “While there could be important reasons to go to an emergency department or urgent care clinic when experiencing a migraine attack, these settings should not usually be the primary source of care,” Dawn B...